-
NHSA Updates NRDL Review, Adds Three Domestic Western Medicines
•
The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction of results related to drugs on the preliminary formal review list of the National Reimbursement Drug List (NRDL). This update follows feedback collected from August 7 to 13, 2024. The revised list now includes 249…
-
Regeneron Secures EU Approval for Ordspono, Its First Bispecific Antibody
•
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has secured its first global market approval for Ordspono (odronextamab) from the European Commission (EC). This marks a significant milestone as Ordspono becomes the company’s first bispecific antibody (BsAb) to receive approval, designated for the treatment of adult patients with relapsed or refractory (R/R) follicular…
-
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate advancements that position the company for future global expansion. For the first half of 2024, BeiGene achieved total operating revenue of USD 1.6808 billion, reflecting a 61.1% year-on-year (YOY) increase. Product revenue surged by 73.0%…
-
Peking Union Medical College Innovates with Angle Positioning Device Patent Sale
•
Peking Union Medical College Hospital (PUMCH) has announced its intention to transfer the patent for its “Angle Positioning Device in Hip Replacement Surgery” to Chinese medical firm AK Medical for RMB 550,000. This innovative device features components for positioning, forward tilt angle measurement, abduction angle measurement, and adjustment mechanisms, enabling…
-
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
•
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD per share for a total of 2,000,000 ordinary shares. The shares have received approval for listing on the Nasdaq Capital Market and are set to begin trading on August 23, 2024, under the ticker symbol…
-
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
•
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced the signing of a definitive agreement to divest its established neurology and allergy business in China. The transaction involves the sale to two prominent investment firms, the Singapore-based CBC Group and the Abu Dhabi-based Mubadala,…
-
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
•
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange (SHE: 002294), has entered into a licensing agreement with fellow Chinese firm YolTech Therapeutics. The agreement grants Salubris exclusive rights to research and development, regulatory filings, manufacturing, and commercial sales of YOLT-101 in mainland China.…
-
Shanghai Fudan-Zhangjiang Enrolls First Patient in Phase III Trial for TROP2 ADC FDA018 in TNBC
•
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1349) and the Shanghai Stock Exchange (SHA: 688505), has announced the enrollment of the first patient in a Phase III clinical study for its drug candidate FDA018. This TROP2 antibody-drug conjugate (ADC) is…
